Several trials investigate TRop2-directed ADCs in various gynecologic cancers (e.g., the TROPION-PanTumor03 study [60]), but there is only one trial that deals with the expression of Trop2 in cervical cancers [29]. Here, TACSTD2 is linked to female reproductive organ cancer.